Testing a blood test to personalize bleeding treatment dosing

This trial is testing whether a blood test called a thrombin generation assay can help doctors personalize the dose of a medicine called aPCC (a clotting medication) for people with hemophilia A who have developed antibodies to standard treatments. You would receive small doses of the medication while researchers measure how your blood clots using this special test. The goal is to figure out the right dose for each person so the medication works better during bleeding episodes or surgery.

People with hemophilia A who develop antibodies to standard treatments need alternative clotting medications, but doctors don't have a reliable way to know what dose works best for each individual. This trial could help personalize dosing and make treatment safer and more effective for future patients.